Cadonilimab (AK104) in the Treatment of Nasopharyngeal Carcinoma
Status:
Recruiting
Trial end date:
2025-09-22
Target enrollment:
Participant gender:
Summary
This study is a phase II clinical study of Cadonilimab (AK104) combined with chemotherapy in
the treatment of PD-1 inhibitor-resistant nasopharyngeal carcinoma.